{
  "meta": {
    "timestamp": "2025-01-06T10:51:42.687236",
    "version": "1.0",
    "type": "search_analysis"
  },
  "companies": [
    {
      "company_name": "CARGO Therapeutics Inc.",
      "symbol": "CRGX",
      "analysis": {
        "historical": {
          "risk_score": 65,
          "key_risks": [
            "Regulatory Hurdles: Stringent FDA and EMA approval processes could delay market entry.",
            "Clinical Trial Uncertainty: Success depends on ongoing trials, which are inherently risky.",
            "Manufacturing Complexity: High complexity and cost of CAR-T production pose scalability and cost control risks.",
            "Market Competition: Intense competition in the CAR-T therapy space may impact differentiation and market share.",
            "Pricing and Reimbursement: High therapy costs may limit patient access and create reimbursement challenges."
          ],
          "controversies": [],
          "environmental_issues": [],
          "social_issues": [
            "High therapy costs may limit patient access, raising ethical concerns about equitable healthcare access."
          ],
          "governance_issues": [],
          "recommendation": "caution",
          "confidence_score": 80
        },
        "evidence": {
          "sources": [
            {
              "url": "",
              "title": "SEC Filing - CARGO Therapeutics, Inc.",
              "snippet": "the timing of achieving our scientific, clinical, manufacturing, regulatory and/or other product development objectives; the timing of our planned Investigational New Drug (IND) application submissions to the United States Food and Drug Administration (FDA) for our product candidates, including firicabtagene autoleucel (firi-cel) (previously ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "CARGO Therapeutics Inc. CARGO Therapeutics Inc. regulatory challenges FDA EMA",
              "retrieved_at": "2025-01-06T17:51:14.717047+00:00",
              "published_date": null,
              "source_hash": "0a2eef1c8c3e61871848712a7fc9ea96"
            },
            {
              "url": "",
              "title": "SEC Filings - CARGO Therapeutics, Inc.",
              "snippet": "The Investor Relations website contains information about CARGO Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "CARGO Therapeutics Inc. CARGO Therapeutics Inc. regulatory challenges FDA EMA",
              "retrieved_at": "2025-01-06T17:51:14.717165+00:00",
              "published_date": null,
              "source_hash": "131685a0f133b7c7aad07d529da7121e"
            },
            {
              "url": "",
              "title": "CARGO Therapeutics, Inc. - AnnualReports.com",
              "snippet": "CARGO Therapeutics, Inc. is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. CARGO's programs, platform technologies, and manufacturing strategy are designed to directly address the limitations of approved cell therapies, including limited durability of ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "CARGO Therapeutics Inc. CARGO Therapeutics Inc. manufacturing lawsuits or disputes",
              "retrieved_at": "2025-01-06T17:51:19.737762+00:00",
              "published_date": null,
              "source_hash": "dd4fe55d135a94a29fe199c9a12a7c77"
            },
            {
              "url": "",
              "title": "SEC Filing - CARGO Therapeutics, Inc.",
              "snippet": "On November 12, 2024, CARGO Therapeutics, Inc. (the \"Company\") announced its financial results for the third quarter ended September 30, 2024. ... During the third quarter, CARGO completed a successful pre-Investigational New Drug (IND) meeting with the FDA, obtaining guidance on the development program and the data package to be provided ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "CARGO Therapeutics Inc. CARGO Therapeutics Inc. regulatory challenges FDA EMA",
              "retrieved_at": "2025-01-06T17:51:14.717197+00:00",
              "published_date": null,
              "source_hash": "7ff54808d0458145ae39c556d5254964"
            },
            {
              "url": "",
              "title": "Cargo, undeterred by market challenges, seeks $281M IPO - Fierce Biotech",
              "snippet": "Cargo, undeterred by market challenges, seeks $281M IPO By Annalee Armstrong Nov 10, 2023 10:00am Cargo Therapeutics biotech IPO Wall Street CAR-T",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "CARGO Therapeutics Inc. CARGO Therapeutics Inc. regulatory challenges FDA EMA",
              "retrieved_at": "2025-01-06T17:51:14.717210+00:00",
              "published_date": null,
              "source_hash": "7583f646486b1b572a00181e26f0dcf3"
            },
            {
              "url": "",
              "title": "CARGO Therapeutics Reports Third Quarter 2024 Financial - GlobeNewswire",
              "snippet": "CARGO Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update... November 12, 2024 16:05 ET | Source: Cargo Therapeutics, Inc. Cargo Therapeutics, Inc.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "CARGO Therapeutics Inc. CARGO Therapeutics Inc. regulatory challenges FDA EMA",
              "retrieved_at": "2025-01-06T17:51:14.717222+00:00",
              "published_date": null,
              "source_hash": "23dcb57574e0ce4957f4c6a09739504e"
            },
            {
              "url": "",
              "title": "Cargo Therapeutics, Inc. (CRGX) 10K Annual Reports & 10Q SEC Filings",
              "snippet": "Exhibit 99.1 CARGO Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and. Provides Business Update - Potentially pivotal Phase 2 clinical study FIRCE-1 of firicabtagene autoleucel (CRG-022) is rapidly recruiting with 20 sites open to date; interim results expected 1H 2025 -. SAN MATEO, Calif., March 21, 2024",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "CARGO Therapeutics Inc. CARGO Therapeutics Inc. regulatory challenges FDA EMA",
              "retrieved_at": "2025-01-06T17:51:14.717273+00:00",
              "published_date": null,
              "source_hash": "38e65c0d50464fc2dd7a36ab9d52230e"
            },
            {
              "url": "",
              "title": "Cargo Therapeutics - Company Profile - Tracxn",
              "snippet": "Cargo Therapeutics - Developer of cell-based therapeutics for cancer treatment. Public Company. Raised a total funding of $200M over 1 round from 15 investors. Founded by Crystal Mackall, Louai Labanieh and 2 others in the year 2021. Cargo Therapeutics has 307 competitors.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "CARGO Therapeutics Inc. CARGO Therapeutics Inc. manufacturing lawsuits or disputes",
              "retrieved_at": "2025-01-06T17:51:19.737856+00:00",
              "published_date": null,
              "source_hash": "315c00b070c39c89ad40d484e556db89"
            },
            {
              "url": "",
              "title": "Pipeline - CARGO Therapeutics",
              "snippet": "Follow CARGO Therapeutics on Twitter. Contact; Pipeline CARGO is advancing a pipeline of transformational next-generation CAR T-cell therapies for cancer. About. ... Stanford and pending data from our ongoing Phase 2 trial in R/R LBCL - post CD19 CAR T we intend to discuss with the FDA initiation of a Phase 2 program in LBCL ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "CARGO Therapeutics Inc. CARGO Therapeutics Inc. regulatory challenges FDA EMA",
              "retrieved_at": "2025-01-06T17:51:14.717301+00:00",
              "published_date": null,
              "source_hash": "643d5fe920a53314b6541da14ea71277"
            },
            {
              "url": "",
              "title": "CARGO Therapeutics Advances in Cancer Therapy Development",
              "snippet": "Additionally, CARGO plans to advance its CRG-023 program, with a successful pre-IND meeting with the FDA and data presentation scheduled at the upcoming ASH 2024 conference.CARGO Therapeutics ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "CARGO Therapeutics Inc. CARGO Therapeutics Inc. regulatory challenges FDA EMA",
              "retrieved_at": "2025-01-06T17:51:14.717314+00:00",
              "published_date": null,
              "source_hash": "2c280b36420f23ec3f4cb1f0e858cc6c"
            },
            {
              "url": "",
              "title": "CARGO Therapeutics, Inc. (NASDAQ:CRGX) Receives Average Recommendation of \"Buy\" from Analysts",
              "snippet": "CARGO Therapeutics, Inc. (NASDAQ:CRGX - Get Free Report) has been assigned an average rating of \"Buy\" from the six brokerages that are presently covering the firm, MarketBeat.com reports. Six investment analysts have rated the stock with a buy rating.",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "CARGO Therapeutics Inc. CARGO Therapeutics Inc. pricing controversies CAR-T therapies",
              "retrieved_at": "2025-01-06T17:51:27.274243+00:00",
              "published_date": "2024-12-30T06:13:00+00:00",
              "source_hash": "cf957978d7a8ac69a41c007b4b6351c5"
            },
            {
              "url": "",
              "title": "CARGO Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update",
              "snippet": "Nov. 12, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical ... following our successful pre-IND meeting with the FDA and we are excited to share more at the upcoming ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "CARGO Therapeutics Inc. CARGO Therapeutics Inc. regulatory challenges FDA EMA",
              "retrieved_at": "2025-01-06T17:51:18.135541+00:00",
              "published_date": "2024-11-12T21:05:00+00:00",
              "source_hash": "42731e82fe5b245060bd6a7e235a5516"
            },
            {
              "url": "",
              "title": "CARGO Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference",
              "snippet": "SAN CARLOS, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next-generation, potentially curative ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "CARGO Therapeutics Inc. CARGO Therapeutics Inc. regulatory challenges FDA EMA",
              "retrieved_at": "2025-01-06T17:51:18.135575+00:00",
              "published_date": "2024-12-17T13:00:00+00:00",
              "source_hash": "eef039d960c0d802d6a1c84631d19521"
            },
            {
              "url": "",
              "title": "CARGO Therapeutics To Present At 43Rd Annual J.P. Morgan Healthcare Conference",
              "snippet": "(MENAFN- GlobeNewsWire - Nasdaq) SAN CARLOS, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc . (NASDAQ: CRGX) , a clinical-stage biotechnology ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "CARGO Therapeutics Inc. CARGO Therapeutics Inc. regulatory challenges FDA EMA",
              "retrieved_at": "2025-01-06T17:51:18.135602+00:00",
              "published_date": "2024-12-17T08:01:00+00:00",
              "source_hash": "ccbb9b5d854247e36ffc3676a89bb131"
            },
            {
              "url": "",
              "title": "SEC Filing - CARGO Therapeutics, Inc.",
              "snippet": "CARGO Therapeutics, Inc. is a clinical-stage biotechnology company positioned to advance next- generation, potentially curative cell therapies for cancer patients. CARGO's programs, platform technologies, and manufacturing strategy are designed to directly address the limitations of approved cell therapies, including limited durability of ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "CARGO Therapeutics Inc. CARGO Therapeutics Inc. manufacturing lawsuits or disputes",
              "retrieved_at": "2025-01-06T17:51:19.737649+00:00",
              "published_date": null,
              "source_hash": "eeaa652f235bd94ab1eb9b51bda2367c"
            },
            {
              "url": "",
              "title": "SEC Filing - CARGO Therapeutics, Inc.",
              "snippet": "We were founded in December 2019 as a Delaware corporation under the name Syncopation Life Sciences, Inc. We changed our name to CARGO Therapeutics, Inc. in September 2022. Our principal executive offices are located at 835 Industrial Road, Suite 400, San Carlos, California 94070, and our telephone number is (650) 379-6143.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "CARGO Therapeutics Inc. CARGO Therapeutics Inc. manufacturing lawsuits or disputes",
              "retrieved_at": "2025-01-06T17:51:19.737781+00:00",
              "published_date": null,
              "source_hash": "604c19af06d832822c33beacee8b82dd"
            },
            {
              "url": "",
              "title": "Manufacturing - CARGO Therapeutics",
              "snippet": "At CARGO, we believe reliable and predictable supply remains a challenge for existing CAR T-cell therapies. To address these challenges, we have developed a potentially commercially suitable manufacturing process that uses an automated and closed platform that is designed to be readily transferrable to multiple manufacturing facilities. Robust Manufacturing Processes Our team is applying its [\u2026]",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "CARGO Therapeutics Inc. CARGO Therapeutics Inc. manufacturing lawsuits or disputes",
              "retrieved_at": "2025-01-06T17:51:19.737795+00:00",
              "published_date": null,
              "source_hash": "fc19e350fd474b57f061eeae8a7f6603"
            },
            {
              "url": "",
              "title": "CARGO Therapeutics, Inc. Company Profile - Dun & Bradstreet",
              "snippet": "Find company research, competitor information, contact details & financial data for CARGO Therapeutics, Inc. of San Carlos, CA. Get the latest business insights from Dun & Bradstreet. CARGO Therapeutics, Inc. D&B Business Directory ... See other industries within the Manufacturing sector: Aerospace Product and Parts Manufacturing , ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "CARGO Therapeutics Inc. CARGO Therapeutics Inc. manufacturing lawsuits or disputes",
              "retrieved_at": "2025-01-06T17:51:19.737814+00:00",
              "published_date": null,
              "source_hash": "70b9293f8540f6ffcf2de92671dc3778"
            },
            {
              "url": "",
              "title": "Cargo Therapeutics Inc. - BioCentury Company Profiles - BCIQ",
              "snippet": "Cargo Therapeutics Inc. - BioCentury Company Profiles for the biopharma industry",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "CARGO Therapeutics Inc. CARGO Therapeutics Inc. manufacturing lawsuits or disputes",
              "retrieved_at": "2025-01-06T17:51:19.737827+00:00",
              "published_date": null,
              "source_hash": "5bf140fabef29124a9e167175c0bf6e7"
            },
            {
              "url": "",
              "title": "CARGO Therapeutics, Inc. (CRGX) Company Profile & Overview - Stock Analysis",
              "snippet": "CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "CARGO Therapeutics Inc. CARGO Therapeutics Inc. manufacturing lawsuits or disputes",
              "retrieved_at": "2025-01-06T17:51:19.737841+00:00",
              "published_date": null,
              "source_hash": "333fe3438ecacada771c46d32418532c"
            },
            {
              "url": "",
              "title": "Cargo Therapeutics, Inc. Company Profile - Dun & Bradstreet",
              "snippet": "Find company research, competitor information, contact details & financial data for Cargo Therapeutics, Inc. of San Mateo, CA. Get the latest business insights from Dun & Bradstreet.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "CARGO Therapeutics Inc. CARGO Therapeutics Inc. manufacturing lawsuits or disputes",
              "retrieved_at": "2025-01-06T17:51:19.737870+00:00",
              "published_date": null,
              "source_hash": "3255de99c9e49e9bcbfb98fae18ae0b5"
            },
            {
              "url": "",
              "title": "CARGO Therapeutics Company Profile | Management and ... - Datanyze",
              "snippet": "CARGO Therapeutics Profile and History. Formerly known as Syncopation Life Sciences, CARGO Therapeutics is a biotechnology company with a focus on CAR T-cell therapies. The company is based in San Mateo, CA.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "CARGO Therapeutics Inc. CARGO Therapeutics Inc. manufacturing lawsuits or disputes",
              "retrieved_at": "2025-01-06T17:51:19.737883+00:00",
              "published_date": null,
              "source_hash": "feb5119d33031c9c7a15d8a3ae3d9e58"
            },
            {
              "url": "",
              "title": "CARGO Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update",
              "snippet": "Nov. 12, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical ... \"With 57 patients dosed and continued, strong manufacturing success, we remain on track to report ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "CARGO Therapeutics Inc. CARGO Therapeutics Inc. manufacturing lawsuits or disputes",
              "retrieved_at": "2025-01-06T17:51:23.187821+00:00",
              "published_date": "2024-11-12T21:05:00+00:00",
              "source_hash": "fa2416a57413e06e3bc47727c237b8c9"
            },
            {
              "url": "",
              "title": "CARGO Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference",
              "snippet": "Dec. 17, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical ... CARGO's programs, platform technologies, and manufacturing strategy are designed to directly address ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "CARGO Therapeutics Inc. CARGO Therapeutics Inc. manufacturing lawsuits or disputes",
              "retrieved_at": "2025-01-06T17:51:23.187931+00:00",
              "published_date": "2024-12-17T08:00:00+00:00",
              "source_hash": "6fd8bd943c7891fb8fe6197b047bbe13"
            },
            {
              "url": "",
              "title": "CARGO Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference",
              "snippet": "CARGO Therapeutics, Inc., a clinical-stage biotechnology company ... CARGO's programs, platform technologies, and manufacturing strategy are designed to directly address the limitations of ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "CARGO Therapeutics Inc. CARGO Therapeutics Inc. manufacturing lawsuits or disputes",
              "retrieved_at": "2025-01-06T17:51:23.187962+00:00",
              "published_date": "2024-12-17T13:11:00+00:00",
              "source_hash": "53393665c52882ae6e181e6c29f5c4ab"
            },
            {
              "url": "",
              "title": "CARGO Therapeutics, Inc. (CRGX) Stock Price, Quote & News - Stock Analysis",
              "snippet": "CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "CARGO Therapeutics Inc. CARGO Therapeutics Inc. pricing controversies CAR-T therapies",
              "retrieved_at": "2025-01-06T17:51:24.668536+00:00",
              "published_date": null,
              "source_hash": "bea304a69d8bbd6165402a2cffdfa9a4"
            },
            {
              "url": "",
              "title": "CARGO Therapeutics, Inc. (CRGX) - Yahoo Finance",
              "snippet": "Find the latest CARGO Therapeutics, Inc. (CRGX) stock quote, history, news and other vital information to help you with your stock trading and investing. ... (CAR) T-cell therapies for cancer ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "CARGO Therapeutics Inc. CARGO Therapeutics Inc. pricing controversies CAR-T therapies",
              "retrieved_at": "2025-01-06T17:51:24.668656+00:00",
              "published_date": null,
              "source_hash": "f90e3f75366601bcb285ec93768e0e35"
            },
            {
              "url": "",
              "title": "CARGO Therapeutics (CRGX) Stock Price, News & Analysis - MarketBeat",
              "snippet": "CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "CARGO Therapeutics Inc. CARGO Therapeutics Inc. pricing controversies CAR-T therapies",
              "retrieved_at": "2025-01-06T17:51:24.668675+00:00",
              "published_date": null,
              "source_hash": "9f4ec3cefb1e8b22b5218c99200c8e73"
            },
            {
              "url": "",
              "title": "CAR-T biotech Cargo Therapeutics prices $281M IPO",
              "snippet": "Cargo's lead program, dubbed CRG-022, is in Phase 2 clinical testing for patients with large B-cell lymphoma that is relapsed or refractory to existing CAR-T therapies. While CAR-T therapies approved by the Food and Drug Administration for lymphoma target a protein called CD19, CRG-022 is aimed at a different protein, CD22. Cargo claims its ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "CARGO Therapeutics Inc. CARGO Therapeutics Inc. pricing controversies CAR-T therapies",
              "retrieved_at": "2025-01-06T17:51:24.668688+00:00",
              "published_date": null,
              "source_hash": "d133a7332cfd39694c0e33a2e1e5535b"
            },
            {
              "url": "",
              "title": "Cargo, undeterred by market challenges, seeks $281M IPO - Fierce Biotech",
              "snippet": "Cargo Therapeutics biotech IPO Wall Street CAR-T Undeterred by the fate of biotechs that have come before it, Cargo Therapeutics is loading up to Wall Street seeking a $281.3 million initial ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "CARGO Therapeutics Inc. CARGO Therapeutics Inc. pricing controversies CAR-T therapies",
              "retrieved_at": "2025-01-06T17:51:24.668701+00:00",
              "published_date": null,
              "source_hash": "33f24659114ed85d89d94610ad411d52"
            },
            {
              "url": "",
              "title": "CARGO Therapeutics, Inc.: Buy Rating Backed by Promising CAR-T ...",
              "snippet": "CARGO Therapeutics, Inc. (CRGX) Company Description: CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "CARGO Therapeutics Inc. CARGO Therapeutics Inc. pricing controversies CAR-T therapies",
              "retrieved_at": "2025-01-06T17:51:24.668712+00:00",
              "published_date": null,
              "source_hash": "0af268348069585de01fd25ffcd4e5d6"
            },
            {
              "url": "",
              "title": "SEC Filing - CARGO Therapeutics, Inc.",
              "snippet": "CARGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware : 84-4080422 ... (CAR) T-cell therapies. A CAR is an engineered protein that is delivered into T cells, enabling recognition and destruction of cancer cells. ... , including any claim or controversy arising out of or relating to the indenture or the ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "CARGO Therapeutics Inc. CARGO Therapeutics Inc. pricing controversies CAR-T therapies",
              "retrieved_at": "2025-01-06T17:51:24.668724+00:00",
              "published_date": null,
              "source_hash": "335a58465b1a039289f12b17dd0a7617"
            },
            {
              "url": "",
              "title": "Cargo Therapeutics Inc Stock - WallStreetZen",
              "snippet": "CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "CARGO Therapeutics Inc. CARGO Therapeutics Inc. pricing controversies CAR-T therapies",
              "retrieved_at": "2025-01-06T17:51:24.668735+00:00",
              "published_date": null,
              "source_hash": "654c503f2afb6861f00a3bcc8d40b01e"
            },
            {
              "url": "",
              "title": "SEC Filing - CARGO Therapeutics, Inc.",
              "snippet": "the pricing and reimbursement of our product candidates, if approved; future agreements with third parties in connection with the potential commercialization of our product candidates; the potential effects of health epidemics, pandemics, other widespread outbreaks of contagious disease, such as COVID-19 and the post-COVID-19 environment, on ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "CARGO Therapeutics Inc. CARGO Therapeutics Inc. pricing controversies CAR-T therapies",
              "retrieved_at": "2025-01-06T17:51:24.668747+00:00",
              "published_date": null,
              "source_hash": "58ecd9ec5186edef0ff46d167268fbaa"
            },
            {
              "url": "",
              "title": "CARGO Therapeutics Inc, CRGX:NSQ profile - FT.com - Financial Times",
              "snippet": "CARGO Therapeutics Inc (CRGX:NSQ) company profile with history, revenue, mergers & acquisitions, ... (CAR) T-cell therapies. The CAR is a protein that has been engineered to modify T cells so they can recognize and destroy ca ncer cells. The Company's lead program, firicabtagene autoleucel (CRG-022), is an autologous (derived from a patient ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "CARGO Therapeutics Inc. CARGO Therapeutics Inc. pricing controversies CAR-T therapies",
              "retrieved_at": "2025-01-06T17:51:24.668758+00:00",
              "published_date": null,
              "source_hash": "51c4ef01bcdb415101ecbf94c0474fdb"
            },
            {
              "url": "",
              "title": "CARGO Therapeutics (NASDAQ:CRGX) Shares Up 5.7% - What's Next?",
              "snippet": "CARGO Therapeutics, Inc. (NASDAQ:CRGX - Get Free Report) shares rose 5.7% on Tuesday . The stock traded as high as $14.54 and last traded at $14.54. Approximately 74,893 shares changed hands during mid-day trading,",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "CARGO Therapeutics Inc. CARGO Therapeutics Inc. pricing controversies CAR-T therapies",
              "retrieved_at": "2025-01-06T17:51:27.274346+00:00",
              "published_date": "2025-01-02T13:55:00+00:00",
              "source_hash": "e8f9bc82070d40c5fd8e64b757d7db11"
            },
            {
              "url": "",
              "title": "CARGO Therapeutics, Inc.: Buy Rating Backed by Promising CAR-T Developments and Positive Clinical Data",
              "snippet": "CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022 ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "CARGO Therapeutics Inc. CARGO Therapeutics Inc. pricing controversies CAR-T therapies",
              "retrieved_at": "2025-01-06T17:51:27.274378+00:00",
              "published_date": "2024-12-09T01:25:00+00:00",
              "source_hash": "407e1bb571bb24e0ff76be613fcd73fb"
            },
            {
              "url": "",
              "title": "Down -14.13% in 4 Weeks, Here's Why CARGO Therapeutics, Inc. (CRGX) Looks Ripe for a Turnaround",
              "snippet": "CARGO Therapeutics, Inc. (CRGX) has been on a downward spiral lately with significant ... This is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. Usually, a stock is considered oversold ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "CARGO Therapeutics Inc. CARGO Therapeutics Inc. pricing controversies CAR-T therapies",
              "retrieved_at": "2025-01-06T17:51:27.274473+00:00",
              "published_date": "2024-12-17T00:50:00+00:00",
              "source_hash": "073376cdb988530c471855490b40dfc3"
            },
            {
              "url": "",
              "title": "CARGO Therapeutics Inc (CRGX)",
              "snippet": "On Thursday, Truist Securities adjusted its price target for Cargo Therapeutics (NASDAQ:CRGX), a biotechnology company, to $32 from the previous $34 while keeping a Buy rating on...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "CARGO Therapeutics Inc. CARGO Therapeutics Inc. pricing controversies CAR-T therapies",
              "retrieved_at": "2025-01-06T17:51:27.274498+00:00",
              "published_date": "2024-12-03T13:47:00+00:00",
              "source_hash": "034bd47ae9d2a60e3db88992fe03b81d"
            }
          ],
          "queries": [
            {
              "category": "financial_legal",
              "query": "CARGO Therapeutics Inc. regulatory challenges FDA EMA",
              "rationale": "Investigate potential delays or issues with regulatory approvals for CAR-T therapies",
              "priority": 1
            },
            {
              "category": "financial_legal",
              "query": "CARGO Therapeutics Inc. manufacturing lawsuits or disputes",
              "rationale": "Identify any legal issues related to the complex production of CAR-T therapies",
              "priority": 2
            },
            {
              "category": "ethical_social",
              "query": "CARGO Therapeutics Inc. pricing controversies CAR-T therapies",
              "rationale": "Explore concerns about high costs and patient access to CARGO's therapies",
              "priority": 3
            }
          ]
        },
        "categorization": {
          "product_issues": [],
          "conduct_issues": [],
          "tags": [],
          "patterns": {}
        }
      },
      "metadata": {
        "analysis_timestamp": "2025-01-06T10:51:42.687242",
        "data_confidence": 80,
        "pattern_confidence": null
      }
    }
  ]
}